Juan Pablo Nicola1, Andrea Reyna-Neyra1, Paul Saenger1, David F Rodriguez-Buritica1, José David Gamez Godoy1, Radhika Muzumdar1, L Mario Amzel1, Nancy Carrasco1. 1. Department of Cellular and Molecular Physiology (J.P.N., A.R.-N., N.C.), Yale University School of Medicine, New Haven, Connecticut 06510; Department of Pediatrics (P.S., J.D.G.G.), Winthrop-University Hospital, Mineola, New York 11501; Department of Genetics (D.F.R.-B.), University of Alabama at Birmingham, Birmingham, Alabama 35294; Department of Pediatrics (R.M.), Albert Einstein College of Medicine, Bronx, New York 10467; and Department of Biophysics and Biophysical Chemistry (L.M.A.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Abstract
CONTEXT: Iodide (I(-)), an essential constituent of the thyroid hormones, is actively accumulated in the thyroid by the Na(+)/I(-) symporter (NIS), a key plasma membrane protein encoded by the slc5a5 gene. Mutations in slc5a5 cause I(-) transport defects (ITDs), autosomal-recessive disorders in which I(-) accumulation is totally or partially impaired, leading to congenital hypothyroidism. The characterization of NIS mutants has yielded significant insights into the molecular mechanism of NIS. OBJECTIVE: This study aimed to determine the basis of a patient's ITD clinical phenotype, by sequencing her slc5a5 gene. DESIGN: Genomic DNA was purified and the slc5a5 gene sequence determined. Functional in vitro studies were performed to characterize the V270E NIS mutant. PATIENT: The index patient was diagnosed with hypothyroidism with minimal radioiodide uptake in a normally located, although enlarged, thyroid gland. RESULTS: We identified a new NIS mutation: V270E. The patient had the compound heterozygous NIS mutation R124H/V270E. R124H NIS has been characterized previously. We show that V270E markedly reduces I(-) uptake via a pronounced (but not total) impairment of the protein's plasma membrane targeting. Remarkably, V270E is intrinsically active. Therefore, a negative charge at position 270 interferes with NIS cell surface trafficking. The patient's minimal I(-) uptake enabled sufficient thyroid hormone biosynthesis to prevent cognitive impairment. CONCLUSIONS: A nonpolar residue at position 270, which all members of the SLC5A family have, is required for NIS plasma membrane targeting.
CONTEXT: Iodide (I(-)), an essential constituent of the thyroid hormones, is actively accumulated in the thyroid by the Na(+)/I(-) symporter (NIS), a key plasma membrane protein encoded by the slc5a5 gene. Mutations in slc5a5 cause I(-) transport defects (ITDs), autosomal-recessive disorders in which I(-) accumulation is totally or partially impaired, leading to congenital hypothyroidism. The characterization of NIS mutants has yielded significant insights into the molecular mechanism of NIS. OBJECTIVE: This study aimed to determine the basis of a patient's ITD clinical phenotype, by sequencing her slc5a5 gene. DESIGN: Genomic DNA was purified and the slc5a5 gene sequence determined. Functional in vitro studies were performed to characterize the V270E NIS mutant. PATIENT: The index patient was diagnosed with hypothyroidism with minimal radioiodide uptake in a normally located, although enlarged, thyroid gland. RESULTS: We identified a new NIS mutation: V270E. The patient had the compound heterozygous NIS mutation R124H/V270E. R124H NIS has been characterized previously. We show that V270E markedly reduces I(-) uptake via a pronounced (but not total) impairment of the protein's plasma membrane targeting. Remarkably, V270E is intrinsically active. Therefore, a negative charge at position 270 interferes with NIS cell surface trafficking. The patient's minimal I(-) uptake enabled sufficient thyroid hormone biosynthesis to prevent cognitive impairment. CONCLUSIONS: A nonpolar residue at position 270, which all members of the SLC5A family have, is required for NIS plasma membrane targeting.
Authors: Irene L Wapnir; Matt van de Rijn; Kent Nowels; Peter S Amenta; Kelly Walton; Kelli Montgomery; Ralph S Greco; Orsolya Dohán; Nancy Carrasco Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: O Levy; G Dai; C Riedel; C S Ginter; E M Paul; A N Lebowitz; N Carrasco Journal: Proc Natl Acad Sci U S A Date: 1997-05-27 Impact factor: 11.205
Authors: Silvia Ravera; Andrea Reyna-Neyra; Giuseppe Ferrandino; L Mario Amzel; Nancy Carrasco Journal: Annu Rev Physiol Date: 2017-02-10 Impact factor: 19.318
Authors: Giuseppe Ferrandino; Juan Pablo Nicola; Yuly E Sánchez; Ignacia Echeverria; Yunlong Liu; L Mario Amzel; Nancy Carrasco Journal: Proc Natl Acad Sci U S A Date: 2016-08-25 Impact factor: 11.205
Authors: Andrea Reyna-Neyra; Lara Jung; Mayukh Chakrabarti; Mikel X Suárez; L Mario Amzel; Nancy Carrasco Journal: Thyroid Date: 2021-06-04 Impact factor: 6.506
Authors: Carlos Eduardo Bernal Barquero; Romina Celeste Geysels; Virginie Jacques; Gerardo Hernán Carro; Mariano Martín; Victoria Peyret; María Celeste Abregú; Patricia Papendieck; Ana María Masini-Repiso; Frédérique Savagner; Ana Elena Chiesa; Cintia E Citterio; Juan Pablo Nicola Journal: Int J Mol Sci Date: 2022-08-17 Impact factor: 6.208